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Anthracycline antibiotics are present one of the most potent antineoplastic drugs. The 
mechanism of their action is complex. They are reported to intercalate to DNA, form 
DNA adducts and interact with topoisomerase II (TopII) as its poisons. Catalytic cycle of 
TopII is interrupted when anthracyclines stabilize the covalent complex of DNA and 
TopII and that causes cell damage. However, using of anthracyclines is limited by several 
adverse effects e. g. myelotoxicity and cardiotoxicity. The mechanism of cardiotoxicity 
is still unclear but may be associated with poisoning of the TopIIβ isoform. Unlike the 
TopIIα, TopIIβ is present mostly in quiescent cells as cardiomyocytes. Furthermore, the 
only clinically approved cardioprotective drug dexrazoxane belongs to TopII catalytic 
inhibitors. Nevertheless, the details of the dexrazoxane-afforded protection are unclear. 
This thesis was aimed to optimize the TARDIS (trapped in agarose DNA 
immunostaining) assay to detect and quantify covalent cleavage complexes, compare 
different ways for analysis of the complexes and finally choose an appropriate type of 
statistical analysis. For our study human leukemic cell line HL-60 and primary rat 
neonatal ventricular cardiomyocytes (NVCM) were used. After incubation with the 
selected drug, the cells were „trapped“ in agarose and lysed. Subsequently the complexes 
were labeled with anti-TopII primary antibody and Alexa Fluor conjugated secondary 
antibody. The acquired signal was then analysed by Cell Profiler program. Using this 
optimized method, we tested the ability of various types of TopII inhibitors (etoposide, 
daunorubicin, XK-469, dexrazoxane and BNS-22) to stabilize cleavage complexes or 
prevent them, respectively.  
 
